Why Forest Laboratories (FRX) Soared on Wednesday

NEW YORK (TheStreet) -- Forest Laboratories (FRX) soared on Wednesday, booking double-digit gains by late morning. The pharmaceutical giant was popping after announcing it had entered into a definitive agreement to acquire privately-held Aptalis, a gastrointestinal and cystic fibrosis specialist.

The acquisition, which will cost Forest $2.9 billion in cash, will be subject to review by anti-trust authorities in the U.S. and Canada. If approved, the deal will be accretive to Forest's earnings by financial year 2015.

"The acquisition of Aptalis helps diversify Forest while advancing our strategy to create blockbuster therapeutic areas," said Forest CEO Brent Saunders in a statement.

As a result of the deal, Forest expects to realize $125 million in cost synergies and to add nearly $700 million in revenue by the next fiscal year.

By late morning, shares had added 16% to $68.16.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing